Events & Presentations
Upcoming Events
Date | Event Details | Remind Me |
---|---|---|
Feb 4, 2021 4:30 PM EST
|
Arrowhead Pharmaceuticals 2021 First Quarter Results
|
Archived Events
Date | Event Details |
---|---|
Sep 25, 2018 12:00 PM EDT
|
Antivirals: Targeting HBV and Beyond
View Presentation 9.9 MB
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “Using siRNA to target the HBV transcriptome”
|
Sep 16, 2018 12:15 PM CDT
|
European Respiratory Society International Congress 2018
View Presentation 1.2 MB
September 16, 12:15 p.m. CEST – Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled, Targeting ENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”
|
Sep 7, 2018 5:45 PM EDT
|
18th World Gastroenterologists Summit
View Presentation 16.1 MB
September 7, 09:45 a.m. NZST – Dr. Given will deliver a keynote presentation titled, “Hepatitis B in focus: New biology, new targets and real hope for finite therapy”
|
Sep 4, 2018
|
Annual B. Riley FBR Healthcare Conference
Bruce Given, M.D., Arrowhead’s chief operating officer, and Vincent Anzalone, CFA, vice president of investor relations, will participate in three panel discussions
|
Aug 7, 2018 4:30 PM EDT
|
Arrowhead Fiscal 2018 Third Quarter Results
View Transcript 137 KB
|
Jun 29, 2018 3:45 PM PDT
|
27th Annual Alpha-1 National Education Conference
View Presentation 9.7 MB
San Francisco, CA
Bruce Given, M.D., will deliver an oral presentation titled, “Development of ARO-AAT, an RNAi based therapeutic for Alpha-1 antitrypsin deficiency-related liver disease”
|
Jun 20, 2018 9:00 AM EDT
|
JMP Securities Life Science Conference
View Presentation 16.1 MB
New York, NY
Bruce Given, M.D., will present a corporate overview
|
Jun 15, 2018 2:15 PM EDT
|
Global Hepatitis Summit 2018
View Presentation 1.5 MB
Toronto
Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver an oral presentation titled, “Interferon-gamma pathway is activated in a chronically HBV infected chimpanzee that controls HBV following ARC-520 RNAi treatment”
|
Jun 8, 2018 5:30 PM +08
|
The Science of HBV Cure 2018
View Presentation 6 MB
Suntec City, Singapore
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB”
|
Jun 6, 2018 3:30 PM EDT
|
Jefferies 2018 Global Healthcare Conference
View Presentation 19.2 MB
New York, NY
Chris Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will present a corporate overview
|